Oncocyte (NASDAQ:IMDX - Get Free Report) issued its quarterly earnings data on Monday. The company reported ($0.19) earnings per share for the quarter, Zacks reports.
Here are the key takeaways from Oncocyte's conference call:
- The FDA said the clinical data in the initial GraftAssureDx submission did not yet support the proposed intended use and requested additional evidence, including an independent accuracy study and expert biopsy-slide reviews. The company expects to submit its response before the January 21, 2027 deadline, but authorization and U.S. launch timing remain dependent on FDA review.
- Insight has begun enrolling patients in its GALACTIC registry, with about five sites expected to be enrolling by year-end, and says beta-site comparisons have shown performance equivalent to legacy tests. Management expects the registry and beta program to generate some revenue and increase clinical familiarity, while cautioning that near-term revenue will be modest.
- The company said transplant centers representing slightly more than 5% of U.S. kidney transplants are committed to developing in-house testing and could launch in 2027. Initial commercialization would focus on larger centers in MolDX jurisdictions, though broader uptake depends on local validation and reimbursement.
- Operating expenses declined from their Q4 2025 peak, with R&D expense at $3.8 million in Q3 versus $5.8 million at the peak; management said operating expenses excluding non-cash items were flat year over year. It also said free cash flow improved and that the FDA-related spending burden is winding down.
- Insight added urine testing for T-cell-mediated rejection to its pipeline and is pursuing heart-transplant testing, with a possible heart submission in the second half of 2027. It also expects to submit kidney and heart applications in Europe around year-end or early January, but said limited reimbursement there currently constrains commercialization.
Oncocyte Price Performance
Shares of IMDX stock traded down $0.22 during trading hours on Monday, reaching $1.92. The company had a trading volume of 174,259 shares, compared to its average volume of 231,577. The company has a 50 day moving average of $3.29 and a 200 day moving average of $4.55. The firm has a market cap of $62.90 million, a price-to-earnings ratio of -1.29 and a beta of 1.90. Oncocyte has a 1-year low of $1.85 and a 1-year high of $7.56.
Wall Street Analysts Forecast Growth
IMDX has been the topic of several research reports. Needham & Company LLC reaffirmed a "buy" rating and set a $9.00 price target on shares of Oncocyte in a research note on Tuesday, August 18th. Weiss Ratings reissued a "sell (d-)" rating on shares of Oncocyte in a report on Monday, September 21st. Finally, Wall Street Zen downgraded shares of Oncocyte from a "hold" rating to a "sell" rating in a research report on Saturday, October 3rd. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Hold" and an average target price of $10.50.
Read Our Latest Report on IMDX
About Oncocyte
(
Get Free Report)
Oncocyte Corporation, now known as Insight Molecular Diagnostics, Inc. NASDAQ: IMDX, is a molecular diagnostics company focused on monitoring organ transplants. Its tests analyze donor-derived cell-free DNA in a transplant recipient's blood to help assess graft health and identify signs of potential injury or rejection. The company's VitaGraft tests include assays for kidney and liver transplant monitoring. These laboratory-developed tests are processed through the company's clinical laboratory and are intended to provide clinicians with information that can complement other aspects of post-transplant care.
Featured Articles

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Oncocyte, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oncocyte wasn't on the list.
While Oncocyte currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.
Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.